Encorafenib
Brand name: Braftovi
Encorafenib comes in 3 pill versions in our database, in 2 strengths, from 2 manufacturers. Check the imprint to tell them apart.
Encorafenib pill images
50 mg 1 pill
75 mg 2 pills
What is Encorafenib used for?
Encorafenib is used for melanoma.
Official uses from the US prescribing label
BRAF V600E or V600K Mutation–Positive Unresectable or Metastatic Melanoma
BRAFTOVI is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-authorized test.
BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (mCRC)
- BRAFTOVI is indicated, in combination with cetuximab and fluorouracil-based chemotherapy, for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-authorized test.
- BRAFTOVI is indicated, in combination with cetuximab, for the treatment of adult patients with mCRC with a BRAF V600E mutation, as detected by an FDA-authorized test, after prior therapy.
BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
BRAFTOVI is indicated, in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-authorized test.
Limitations of Use
BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC.
From the FDA-approved label on DailyMed (published Mar 02, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.